BERGENBIO TO PRESENT AT ABG SUNDAL COLLIER LIFE SCIENCE SUMMIT
Bergen, Norway, 16 May 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, is pleased to announce that CEO Martin Olin will be presenting at the ABG Sundal Collier Life Science Summit taking place on Wednesday 18 May at 11:30 CEST. The presentation slides will be made available on the Company's website in the Investors section shortly after the presentation. -Ends- Contacts Martin Olin CEO, BerGenBio ASA ir@bergenbio.com Rune Skeie, CFO, BerGenBio ASArune.skeie@